Question special
Lead Moderator

Hello everyone! Thank you to all of the authors and experts for their participation in this forum. I am looking forward to our discussion on the article titled "Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease" over the next week. Let's jump right in:

This study was a large-scale, randomized trial where the rates of target-lesion failure at 1 year were 1.7 percentage points higher in the Absorb group than in the Xience group. This was a nonsignificant difference that met the study criteria for noninferiority. What are the initial thoughts and takeaway points from these study results? Was the 1-year time point too short to identify benefits?